Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clin... (ry incontinence increased saliva constip...)

HOME >> MEDICINE >> TECHNOLOGY

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Date:5/6/2008

ry incontinence, increased saliva, constipation, fever, tremors, muscle stiffness, abdominal pain, anxiety, nausea, dizziness, dry mouth, rash, restlessness, and indigestion.

The most common side effects that occurred with RLAI were sleepiness, restlessness, tremors and muscle stiffness, stomach upset, constipation, dry mouth, feeling tired, and weight increase.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with risperidone, RLAI, and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with risperidone, RLAI, and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

Risperidone and RLAI should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Risperidone, RLAI, and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The co
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
8. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
9. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
10. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

Post Your Comments:

(Date:5/20/2013)... MINNEAPOLIS , May 20, 2013 Uroplasty, Inc. ... will release financial results for the fiscal fourth quarter ... market close on Thursday, May 30, 2013. The Company ... these results on Thursday, May 30, 2013 at 4:30 ... to participate in the conference call should dial 888-549-7750, ...

(Date:5/20/2013)... Quebec , May 20, 2013 Valeant Pharmaceuticals International, ... members of its senior management team will make a presentation ... on Tuesday, June 11, 2013 at 9:20 a.m. PT. The ... Los Angeles, CA. A live ... on the company,s Web site at www.valeant.com . Click ...

(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Today at American Society ... Christine Ginocchio discussed Specific Technologies blood ... identification of microorganisms producing bloodstream infection. Dr. Ginocchio ... the Division of Infectious Disease Diagnostics at North ... non-sectarian health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ...

Breaking Medicine Technology:Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2 Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3

[0] Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 [0] Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference [0] Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio

... IDM Pharma, Inc.,(the Company) (Nasdaq: IDMI ) ... clinical protocol finalized with the U.S. Food and ... osteosarcoma patients through a compassionate access study., ... increasing number of,requests for compassionate access to L-MTP-PE," ...

... not the Only Way We Suffer - ... Allergies Impact Mood and Self-Perception, KENILWORTH, N.J. and ... about 50,million people in the United States.(1)(2) Yet, according to ... a nuisance: in today,s society allergies get little respect.,As a ...

Cached Medicine Technology:IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 2 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 3 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 4 IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 2 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 3 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 4 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 5 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 6 New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 7

IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly

(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...

(Date:5/20/2013)... (PRWEB) May 21, 2013 People are so ... Stress levels are through the roof and are contributing ... handle this stress could mean the difference between life and ... Begin’ event on 29 May will share valuable, practical tools ... and influence the world around them for social good. , ...

(Date:5/20/2013)... According to a May 6, 2013 CBS News ... tanning salons in the US may soon have ... wants to see cancer warnings on indoor tanning beds ... eighteen for the use of indoor tanning and sun beds. ... become increasingly common over the last few decades (Go to ...

(Date:5/20/2013)... MI (PRWEB) May 20, 2013 ... Lupus Foundation will be holding ... in Lansing on June 10th. ... June 10th, 6:30 p.m. – ... Building (Across from Sparrow Hospital), ...

(Date:5/20/2013)... to a June 2009 Bloomberg article, it is estimated ... $3.6 billion dollars per year (i). Additionally, in ... 15 million incidents of medical harm each year (ii). ... any form of medical treatment should be aware of ... as “a dereliction of professional duty or a failure ...

Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2 Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2

[0] Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference [0] Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Lupus Support Group Meeting in Lansing on June 10th [0] Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases

... OF MICHIGAN URGES DETROIT EMPLOYERS TO SEE INFLUENZA AS ... in billions of dollars in lost wages every year, ... missed workdays a year, and about 200 million days ... Yet vaccination rates remain alarmingly low, especially among working ...

... and continued positive cash flow from operationsBOSTON, Feb. ... ), a leader in radiology and medical image ... results for the fourth quarter and year ended ... Q4 Financial Highlights Revenue : Total revenue ...

... - Conference call on Thursday, February 26, 2009, at 9:00 ... International (NYSE: SCI ), a leading provider of ... quarter and fiscal year 2008 and provided its comments on ... statements can be found at the end of this press ...

... Pharmaceuticals to increase access to radiological threat antidoteWASHINGTON, ... agreement in principle with Fleming Pharmaceuticals for the ... ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, ... at risk of exposure to radioactive iodine. It ...

... Feb. 25 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... live webcast on Tuesday, March 3, 2009 at 9:00 am EST ... 31, 2008. The Company will release results after the market ... be available on the Par website at www.parpharm.com .Access to ...

... growing twice as fast as San Diego.The system rewards physicians ... Feb. 25 The cost of providing health care to ... as in San Diego, and Medicare now spends nearly three ... it does in Honolulu. This illustrates how huge inefficiencies in ...

Influenza Infection Costs Employers Billions Each Year; Working Adults Largest Group Not Immunized Annually AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009 Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)Par Pharmaceutical to Host Fourth Quarter and Full Year 2008 Results Conference Call on March 3 at 9:00 am Taming Wide Variations in Spending Key to Health Reform - New England Journal of Medicine Commentary from Dartmouth Atlas Project

... membrane parasite soluble lysate ... as antigen. Since this ... than the recombinant kit, ... use two ELISA techniques ...

The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....

... The dual-electrode SPL defibrillator lead ... design, offering the flexibility and ... Designed for the physician who ... shocking coils, the SPL lead ...

... The Medtronic Subcutaneous Lead ... implanted subcutaneously with the use ... Model 6996T. Improved SQ design ... DFTs, a fast and easy ...

Medicine Products:

Chagatest ELISA T. cruzi IgG CELISA SPL™ Leads Subcutaneous Lead System Model 6996SQ